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Abstract: Perineuronal nets (PNNs) are extracellular matrix structures surrounding neuronal
sub-populations throughout the central nervous system, regulating plasticity. Enzymatically
removing PNNs successfully enhances plasticity and thus functional recovery, particularly in spinal
cord injury models. While PNNs within various brain regions are well studied, much of the
composition and associated populations in the spinal cord is yet unknown. We aim to investigate the
populations of PNN neurones involved in this functional motor recovery. Immunohistochemistry
for choline acetyltransferase (labelling motoneurones), PNNs using Wisteria floribunda agglutinin
(WFA) and chondroitin sulphate proteoglycans (CSPGs), including aggrecan, was performed to
characterise the molecular heterogeneity of PNNs in rat spinal motoneurones (Mns). CSPG-positive
PNNs surrounded ~70–80% of Mns. Using WFA, only ~60% of the CSPG-positive PNNs co-localised
with WFA in the spinal Mns, while ~15–30% of Mns showed CSPG-positive but WFA-negative PNNs.
Selective labelling revealed that aggrecan encircled ~90% of alpha Mns. The results indicate that
(1) aggrecan labels spinal PNNs better than WFA, and (2) there are differences in PNN composition
and their associated neuronal populations between the spinal cord and cortex. Insights into the role
of PNNs and their molecular heterogeneity in the spinal motor pools could aid in designing targeted
strategies to enhance functional recovery post-injury.
Keywords: perineuronal nets; spinal cord; alpha motoneurone; gamma motoneurone; chondroitin
sulphate proteoglycans
1. Introduction
Perineuronal nets (PNNs) are dense specialised extracellular matrix (ECM) structures that
surround neuronal sub-populations throughout the central nervous system (CNS). First described
by Golgi as reticular structures in the late 1800s [1], PNNs have since been implicated in pathologies
of various neurological disorders, including Alzheimer’s disease, epilepsy and schizophrenia [2–5],
as well as in traumatic CNS injuries [6], particularly spinal cord injury (SCI) models [7,8]. A key role
of PNNs is their involvement in the termination of developmental plasticity, where they form an
interdigitating mesh with mature somatic and dendritic contacts to confer synaptic stabilisation [9–11].
PNNs are composed of a compact arrangement of a variety of neural ECM proteoglycans and
proteins [12,13]. These components primarily consist of chondroitin sulphate proteoglycans (CSPGs)
including the hyaluronan (HA) binding CSPGs called lecticans, bound upon a long HA backbone
and stabilised by the HA and proteoglycan link proteins (HAPLNs) and tenascin-R [14]. Upon this
basic PNN structure, the binding of other CSPGs (such as phosphacan) are thought to provide much
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of the heterogeneity of PNNs [15]. CSPGs are composed of chondroitin sulphate glycosaminoglycan
(CS-GAG) chains attached to a core protein that differentiates the various CSPGs from one another [15].
CS-GAGs confer a further vast degree of heterogeneity through variation of expression, chain length
and sulphation patterns, even to the same core protein [16,17].
Although many studies have investigated the molecular heterogeneity of PNNs in distinct
neuronal populations in regions of the brain [18–21], much of the composition and associated
populations in the spinal cord is relatively unknown. Similar to the brain [22], in the spinal cord
many of the known cells enwrapped by PNNs are fast-spiking inhibitory parvalbumin (PV)-positive
interneurones (approximately half) [23,24], and have also been associated with calbindin-positive
Renshaw cells [22]. However, in contrast to the brain, reports suggest that PNNs in the spinal
cord also surround cells with large neuronal cell bodies, particularly within the ventral horn likely
representingmotoneurones (Mns) [22,25–27]. Mns are a heterogeneous population of neurones with the
main subclasses, alpha and gamma Mns, innervating contractile extrafusal fibres and proprioceptive
intrafusal fibres within the motor unit, respectively [28].
Enzymatic removal of PNNs using chondroitinase ABC (ChABC) after CNS injury has been shown
in multiple models, predominately SCI, to reopen a window of plasticity to promote improvements
in motor functions [7,8]. Regeneration of descending tracts can contribute to this functional
recovery [29,30]; however, the extent and mechanism of changes in local spinal circuitry attributing to
this recovery remains unclear. Additionally, studies also implicate exercise and rehabilitative training
to activity-dependant modulation of PNNs in the ventral motor pools [31,32], suggesting a relationship
between PNNs and Mns that is important for normal motor functions.
This study therefore aims to investigate the normal expression and molecular composition
of PNNs in the spinal motor pools; the population of PNN-associated neurones in the spinal
cord likely to be involved in functional motor recovery after SCI, and to identify the best PNN
marker for this population. Immunohistochemical staining was performed using antibodies against
choline acetyltransferase (ChAT), a marker of spinal Mns [33], alongside labelling for primary PNN
components, including various CSPGs and the acclaimed “universal” PNN markerWisteria floribunda
agglutinin (WFA), to elucidate the composition of PNNs associated with spinal motor circuitry.
Selective staining for the primary functional Mn subclasses was combined with PNN labelling to
categorise PNN expression within the motor pool. It was found that distinct populations of Mns were
surrounded by PNNs labelled by various CSPGs yet lacking WFA, indicating a difference between
the composition of PNNs and associated neuronal cell types in the brain and spinal cord. PNNs were
found to surround the majority of alpha Mns, suggesting that these are the main populations affected
by ChABC-mediated recovery after SCI.
2. Results
We aim to determine the molecular heterogeneity of PNNs in the spinal cord, with a particular
focus to the Mns in the ventral horn. Spinal cord sections from three different spinal levels, cervical,
thoracic and lumbar, were used to compare the spatial differences of PNNs. Alongside ChAT staining,
we also stained for WFA, a common PNN marker [6,7,10,34], and for CSPGs including aggrecan
(ACAN), brevican (BCAN), neurocan (NCAN), versican (VCAN) and phosphacan (PTPRZ).
2.1. WFA-Positive PNNs Only Partially Overlap with Other CSPGs in the Ventral Motor Pools
2.1.1. ACAN
ACAN is a CSPG in the lectican family and is widely considered to be a major component in
PNNs [2,35,36]. Immunohistochemical staining of ACAN core protein illustrated clear expression of
PNNs surrounding ventral Mns labelled with ChAT (Figure 1J–L). ACAN-positive PNNs surrounded
approximately 85% of ChAT-positive Mns in all levels of the spinal cord investigated (Figure 1A–C).
In comparison, WFA-positive PNNs enwrapped significantly fewer Mns (approximately 68% of the
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ChAT-positive Mns) than ACAN-positive PNNs (cervical p < 0.001, thoracic p < 0.05 and lumbar p < 0.01;
n = 4), illustrating that WFA does not label all PNNs in the ventral motor pools. Compounding this,
the total number of ACAN-positive PNNs surrounding Mns was significantly greater than the number
of ACAN+/WFA+ PNNs (cervical p < 0.001, thoracic p < 0.05, lumbar p < 0.01; n = 4). ACAN and WFA
PNN populations appeared to overlap (Figure 1D–I). Further breakdown of PNN type revealed that,
at each level, all PNNs that are positive for WFA co-localised with ACAN (n.s.; p = 1). No investigated
PNNs were WFA-positive and ACAN-negative. The results demonstrate that ACAN labels a larger
population of PNN-positive Mns, and suggest that it is a better marker for PNN in the spinal cord.
Figure 1. Comparison of perineuronal nets (PNNs) in the spinal ventral motor pools labelled by
Wisteria floribunda agglutinin (WFA) and aggrecan (ACAN). (A–C) Bar graphs showing percentage
of ChAT-positive motoneurones (Mns) in the ventral motor pools surrounded by ACAN-positive
and WFA-positive PNNs and their co-localisation (ACAN+/WFA+) in cervical (A), thoracic (B) and
lumbar (C) rat spinal cord. Error bars ± SD; n = 4. Statistics one-way ANOVA; significance levels:
* p < 0.05, ** p < 0.01, *** p < 0.001. Confocal images showing ACAN-positive (D–F) and WFA-positive
(G–I) PNNs surrounding ChAT-positive Mns (J–L) in the cervical, thoracic and lumbar spinal cord,
respectively. Scale bars, 100 µm.
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2.1.2. BCAN
BCAN is a lectican CSPG found specifically in the CNS with growing evidence of its importance
in regulating the plastic properties of PNNs [37]. Co-staining with ChAT-positive neurones in the
ventral horn revealed a high degree of localisation, with approximately 88% of Mns encircled by
BCAN-positive PNNs (Figure 2A–C). Similar to ACAN, WFA-positive PNNs appeared to denote
some but not all of the BCAN-positive PNN-ensheathed Mns, labelling approximately 30% fewer
Mns than BCAN (all levels p < 0.001; n = 5). BCAN+/WFA+ PNNs in the motor pools appeared to
represent a proportion that is significantly less that the total BCAN-positive PNN population (all levels
p < 0.001; n = 5). Additional categorisation again revealed that all WFA-positive PNNs in the motor
pool co-localised with BCAN-positive PNNs.
Figure 2. Comparison of perineuronal nets (PNNs) in the spinal ventral motor pools labelled by
Wisteria floribunda agglutinin (WFA) and brevican (BCAN). (A–C) Bar graphs showing percentage
of ChAT-positive motoneurones (Mns) in the ventral motor pools surrounded by BCAN-positive
and WFA-positive PNNs and their co-localisation (BCAN+/WFA+) in cervical (A), thoracic (B) and
lumbar (C) rat spinal cord. Error bars ± SD; n = 5. Statistics one-way ANOVA; significance levels:
*** p < 0.001. Confocal images showing BCAN-positive (D–F) andWFA-positive (G–I) PNNs surrounding
ChAT-positive Mns (J–L) in the cervical, thoracic and lumbar spinal cord, respectively. Scale bars, 100 µm.
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2.1.3. NCAN
NCAN is a nervous system-specific lectican, like BCAN, known to be present in PNNs in the
spinal cord [18,22,38]. In the ventral horn, NCAN staining revealed PNNs encircling approximately
87% of Mns (Figure 3A–C). Echoing the trend with ACAN and BCAN, WFA-positive PNNs enveloped
28% fewer Mns than NCAN (all levels p < 0.001; n = 5). Significantly, only approximately two-thirds
of these NCAN-positive PNNs co-localised with WFA (all levels p < 0.001; n = 5). No WFA-positive
PNNs lacking NCAN co-staining were observed, signifying that all WFA co-localised with NCAN.
Figure 3. Comparison of perineuronal nets (PNNs) in the spinal ventral motor pools labelled by
Wisteria floribunda agglutinin (WFA) and neurocan (NCAN). (A–C) Bar graphs showing percentage
of ChAT-positive motoneurones (Mns) in the ventral motor pools surrounded by NCAN-positive
and WFA-positive PNNs and their co-localisation (NCAN+WFA+) in cervical (A), thoracic (B) and
lumbar (C) rat spinal cord. Error bars ± SD; n = 5. Statistics: one-way ANOVA; significance
levels: *** p < 0.001. Confocal images showing NCAN-positive (D–F) and WFA-positive (G–I) PNNs
surrounding ChAT-positive Mns (J–L) in the cervical, thoracic and lumbar spinal cord, respectively.
Scale bars, 100 µm.
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2.1.4. VCAN
VCAN staining revealed intense diffuse ECM expression in both the white and gray matter of the
spinal cord due to its expression in the nodes of Ranvier [18,39,40]. VCAN did not show strong PNN
staining in laminae other than the ventral horn. In the ventral horn, VCAN-positive PNNs surrounded
approximately 82% of Mns at all spinal levels (Figure 4A–C). WFA and VCAN populations of PNNs
showed a clear overlap at all spinal levels (Figure 4D–L). However, all WFA-positive PNNs co-localised
with VCAN with a significant population of VCAN-positive PNNs WFA-negative (all levels p < 0.001;
n = 4).
Figure 4. Comparison of perineuronal nets (PNNs) in the spinal ventral motor pools labelled by
Wisteria floribunda agglutinin (WFA) and versican (VCAN). (A-C) Bar graphs showing percentage of
ChAT-positive motoneurones (Mns) in the ventral motor pools surrounded by VCAN-positive and
WFA-positive PNNs and their co-localisation (VCAN+/WFA+) in cervical (A), thoracic (B) and lumbar
(C) rat spinal cord. Error bars ± SD, n = 4. Statistics: one-way ANOVA; significance levels: * p < 0.05,
** p < 0.01, *** p < 0.001. Confocal images showing VCAN-positive (D–F) andWFA-positive (G–I) PNNs
surrounding ChAT-positive Mns (J–L) in the cervical, thoracic and lumbar spinal cord, respectively.
Scale bars, 100 µm.
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2.1.5. PTPRZ
Phosphacan or PTPRZ is a non-HA binding CSPG that represents the extracellular domain of
protein tyrosine phosphatase receptor zeta (PTPRZ) modified by glial cells [41,42] and has been found
to be present in WFA-positive PNNs in the cerebral cortex [18,22,43]. Immunohistochemistry showed
that PTPRZ is also found in PNNs in the ventral motor pool, surrounding approximately 76% of Mns
in all levels of the cord studied (Figure 5A–C). However, in all levels of the spinal cord investigated,
PTPRZ-positive PNNssurrounded 15% more Mns than WFA (all levels p < 0.01; n = 4), reiterating the
trend shown by the lecticans above. Approximately 82% of PTPRZ-positive PNNs were also labelled
by WFA, representing a significantly lower proportion of the total observed PTPRZ-positive PNNs in
the motor pool (all level p < 0.05; n = 4).
Figure 5. Comparison of perineuronal nets (PNNs) in the spinal ventral motor pools labelled by
Wisteria floribunda agglutinin (WFA) and phosphacan (PTPRZ). (A–C) Bar graphs showing percentage
of ChAT-positive motoneurones (Mns) in the ventral motor pools surrounded by PTPRZ-positive and
WFA-positive PNNs and their co-localisation (PTPRZ+/WFA+) in cervical (A), thoracic (B) and lumbar
(C) rat spinal cord. Error bars ± SD; n = 4. Statistics: one-way ANOVA; significance levels: * p < 0.05,
** p < 0.01. Confocal images showing PTPRZ-positive (D–F) and WFA-positive (G–I) PNNs surrounding
ChAT-positive Mns (J–L) in the cervical, thoracic and lumbar spinal cord, respectively. Scale bars, 100 µm.
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2.2. Distinct Populations of CSPG-Positive yet WFA-Negative PNNs in the Motor Pools
For each CSPG investigated, a significant percentage of Mns were surrounded by PNNs that
were CSPG-positive yet WFA-negative (all levels, all CSPGs p < 0.001). The percentage of Mns
with WFA-negative PNNs varied with CSPG investigated (Figure 6). While ACAN+/WFA−,
VCAN+/WFA− and PTPRZ+/WFA− PNNs encircled roughly 15% of Mns (Figure 6A,D,E), a higher
percentage of Mns (approximately 30%) appeared to be surrounded by BCAN+/WFA− and
NCAN+/WFA− PNNs (Figure 6B,C). Overall, the results suggest that in the ventral motor pools, WFA
does not denote all PNNs, and instead distinct populations of Mns with CSPG-positive, WFA-negative
PNNs exist.
Figure 6. A proportion of perineuronal nets (PNNs) in the spinal motor pools were negative forWisteria
floribunda agglutinin (WFA). Percentage of ChAT-positive motoneurones in the ventral motor pools
in the cervical, thoracic and lumbar spinal cord surrounded by CSPG-positive, WFA-negative PNNs.
(A) Aggrecan (ACAN, n = 4); (B) brevican (BCAN, n = 5); (C) neurocan (NCAN, n = 5); (D) versican
(VCAN, n = 4); and (E) phosphacan (PTPRZ, n = 4). Error bars ± SD. Statistics one-way ANOVA; n.s.
2.3. Alpha Mns Are Preferentially Surrounded by PNNs
Using NeuN and ChAT co-labelling, Mns in the spinal ventral motor pools were selectively
labelled as either alpha (NeuN-positive) or gamma (NeuN-negative) [31,44]. It was observed that
approximately 70–80% of ChAT-positive Mns were NeuN-positive (Figures 7 and 8), signifying
thealpha Mn population. Firstly, as the universal marker for PNNs, WFA was used to determine
the number of PNNs surrounding each Mn subtype. Similarly to the results above, WFA-positive
PNNs surrounded approximately 60% of all Mns with approximately 98% of these PNNs surrounding
NeuN-positive Mns (alphas; Figure 7A–C). In other words, a significant proportion of alpha Mns
(~72%) were associated with WFA-positive PNNs (cervical and lumbar p < 0.001, thoracic p < 0.05;
n = 3). As previous findings illustrated that in the ventral motor pools, WFA did not label all Mns,
ACAN was also used to identify PNNs around Mn subtype. Again, most PNNs (95%) surrounded
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alpha Mns (Figure 8A–C). ACAN-positive PNNs encircled roughly 90% of alpha Mns, suggesting that
PNN-positive Mns and alpha Mns are the same population.
Figure 7. Wisteria floribunda agglutinin (WFA)-positive PNNs surrounded some but not all alpha
motoneurones (Mns). (A–C) Bar graphs showing percentage of ChAT-positive Mns in the ventral motor
pools surrounded by NeuN, WFA-positive PNNs and their co-localisation (WFA+/NeuN+) in cervical
(A), thoracic (B) and lumbar (C) rat spinal cord. NeuN and ChAT co-localisation denotes alpha Mns.
Error bars ± SD; n = 3. Statistics: one-way ANOVA; significance levels: * p < 0.05, *** p < 0.001. Confocal
images showingWFA-positive PNNs (D–F) surrounding NeuN-positive (G–I) PNNs and ChAT-positive
Mns (J–L) in the cervical, thoracic and lumbar spinal cord, respectively. Scale bars, 100 µm.
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Figure 8. Aggrecan (ACAN)-positive PNNs surrounded most alpha motoneurones (Mns). (A–C) Bar
graphs showing percentage of ChAT-positive Mns in the ventral motor pools surrounded by NeuN,
ACAN-positive PNNs and their co-localisation (ACAN+/NeuN+) in cervical (A), thoracic (B) and
lumbar (C) rat spinal cord. NeuN and ChAT co-localisation denotes alpha Mns. Error bars ± SD; n = 3.
Statistics: one-way ANOVA; significance levels: * p < 0.05. Confocal images showing ACAN-positive
PNNs (D–F) surrounding NeuN-positive (G–I) PNNs and ChAT-positive Mns (J–L) in the cervical,
thoracic and lumbar spinal cord, respectively. Scale bars, 100 µm.
3. Discussion
As removal of PNNs in the spinal cord after injury enhances motor recovery, we looked to
investigate the expression of PNNs and their heterogeneity in spinal Mns; the final order neurones for
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the control of voluntary movement. This is the first article to systemically and quantitatively compare
the differences of CSPG- or WFA-positive PNNMns in the ventral motor pools. Mns were identified
using an antibody against ChAT to label cholinergic neurones alongside markers for PNN components
and the acclaimed universal PNNmarkerWFA in comparison. We demonstrated that a high proportion
of Mns in the ventral spinal cord were surrounded by PNNs, particularly alpha Mns. Unexpectedly,
the universal marker for PNNs, WFA, did not label all of the PNNs with distinct populations of Mns
surrounded by CSPG-positive yet WFA-negative PNNs. This suggests that, in contrast to the brain,
WFA does not label the majority of PNN neurones in the ventral spinal cord and that studies using
WFA in the spinal cord may be underestimating the number of PNNs.
3.1. PNNs in the Spinal Ventral Motor Pools
Previous studies have described ventral Mns as the most conspicuous neuronal population in
the spinal cord to be surrounded by PNNs and this appears to be conserved across mammalian
species [25,31,32,45,46]. Despite this, few studies have actually investigated the proportion of PNNs in
the ventral motor pools and those that do use varying markers to determine this. Comparable to our
own methods, using ChAT as a specific Mn marker, a similar proportion of ventral Mns was observed
to be surrounded by PNNs to that found in our study (~80%) has been reported in non-human
primates (75%), using WFA [45], and in human (71%) spinal cord, using ACAN [46]. In rats, however,
this distribution has been investigated with the general neuronal marker (NeuN) using size and ventral
location to identify Mns alongside WFA lectin staining to characterise PNN expression, resulting in
estimates of only 30% of Mns associated with PNNs [25]. This is likely to underestimate for two
reasons: (1) without a Mn-specific neuronal marker small sized Mns, including NeuN-negative gamma
Mns [44,47], would have been absent from these counts, and (2) WFA does not appear to label all
PNNs in the rat spinal cord. Indeed, our findings suggest that PNNs are present in almost 80% of the
ChAT-positive Mns.
Although others have implicated that PNNs only surround large cell-bodied Mns in the motor
pools, i.e., alpha Mns and not gamma Mns [25,31], we are the first to systematically categorise
the proportion of specific Mn-subtypes associated with PNNs at different levels of the spinal cord.
Despite contributing to the same goal of voluntary muscle control, alpha and gamma Mns represent
distinct populations of Mns within the ventral motor pools, differing in both electrical and molecular
properties [28,44,48,49]. These differences also include the innervation of different muscle targets,
with alpha Mns responsible for force generation though contraction of extrafusal fibres whereas
gamma Mns innervate the intrafusal fibres regulating muscle spindle sensitivity. The high proportion
of enveloped alpha Mns revealed likely reflects the importance of the role of PNNs in providing
synaptic stabilisation of inputs from the specific spinal circuitry and consequent contractile innervation
of key muscle groups. After SCI, the stabilisation of synaptic plasticity conferred by PNNs instead
becomes another mechanism inhibiting regenerative attempts and compensatory rearrangements of
spared fibres. We suggest that ChABC-mediated removal of PNNs in SCI models is therefore able to
induce a high degree of enhanced plasticity of synaptic connections to the abovementioned populations
of alpha Mns contributing to the observed improvement of most functional motor recovery studies.
3.2. Differences in PNNs between the Brain and Spinal Cord
It is generally assumed that PNNs in the brain and the spinal cord are the same. While in the
brain, WFA does not always co-localise with ACAN as previously discussed, other CSPG-positive
PNNs always co-localise with WFA. Here, we demonstrate differences in the composition of PNNs
between the brain and spinal cord, where ACAN and other CSPGs denote subclasses of Mns in the
spinal cord lacking WFA. This study recommends that future staining for PNNs associated with the
spinal motor pools, particularly SCI studies utilising therapies that modify PNNs such as ChABC,
should seek alternatives to WFA to avoid underestimating total PNN number.
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Additionally, brain PNNs are well known to target small fast-spiking inhibitory interneurones
playing a modulatory role in the brain [50]. In sharp contrast, the associated neuronal populations
studied here are large cell bodied neurones acting as the primary endpoint of neural control of the
somatic motor system. Other neuronal cell types such as calbindin-positive Renshaw cells in the
ventral spinal cord are surrounded by PNNs [22], further implicating the role of PNNs in stabilisation
of connections within the spinal motor circuitry. In a recent systematic review of the CNS, motor
regions, including the cerebellum and spinal cord, were more likely to have a higher proportion
of neurones surrounded by PNNs than sensory structures [45]. It is possible that PNNs may have
different roles in different parts of the nervous system or with different neuronal populations.
3.3. Composition of PNNs in the Spinal Motor Pools
Staining with the lectin WFA and antibodies for various CSPG core proteins revealed two distinct
types of distributions throughout the grey matter: diffuse extracellular staining and a bright ‘halo’
of pericellular expression identifying the PNNs. The overall distributions of immunoreactivities
for the CSPGs investigated and ChAT were generally similar to previous descriptions [18,22,25,33].
We showed that all of the CSPGs investigated were present in PNNs surrounding spinal Mns.
These were also found to be present to varying degrees, indicating heterogeneity of PNNs in the
motor pools.
ACAN in particular has been previously reported to be present in PNNs surroundingMns [22,51,52],
as well as BCAN, NCAN, VCAN and PTPRZ. It is estimated that VCAN begins to appear in PNNs
around the Mns from postnatal day 8 [53]. Studies in the brain and spinal cord show that ACAN is
present in all PNNs and generally co-localises with WFA expression [12,18,25]. However, consistent
with all CSPGs investigated, WFA does not appear to show all PNN-associated neurones in the ventral
motor pools. As WFA is supposed to bind to the CS-GAG sugar N-acetylgalactosamine (GalNAc) [50],
it should bind to all CSPGs and therefore denote all PNNs. However, binding of WFA has previously
been shown to be dependent on the presence of ACAN [12] and recently other studies in various
regions of the brain, including the hippocampus, have reported PNNs with ACAN labelling but no
WFA binding [21,54]. In the spinal cord, we observed a lack of WFA in ACAN-positive PNNs to a
similar degree to that observed in the CA1 area of the hippocampus [21], appearing to denote distinct
populations of Mns. As there is a vast degree of heterogeneity of CS-GAGs within CSPGs, further
research is required to determine the conditions of WFA binding. It is possible that the molecular
composition of CSPGs within PNNs may confer functional subclasses of Mns.
The expression of many PNN components such as ACAN, BCAN and tenascin-R show differences
in expression between various brain regions [55]. In particular, BCAN is usually found at the
para-nodal regions and has been shown to regulate the localisation of potassium channels and AMPA
receptors [37]. The mechanism of how brevican performs these functions remains to be determined.
Expression of CSPGs in PNNs across the spinal laminae has also been shown to display differential
expression [22,25]. PNNs are a dynamic network of ECM components. Activity-dependant modulation
has been demonstrated where the thickness of PNNs surrounding spinal Mns increases in response
to exercise or rehabilitative training [31,32]. This is likely conveyed through dynamic regulation of
CSPGs and/or CS-GAGs within the PNNs. There is a growing concept that the properties of the ECM
have an important influence in both healthy and pathological states. Though it is beyond the scope of
this study, it is hoped that further research into the heterogeneity of PNNs in CNS regions may help to
unravel the functionality of these ECM components and their alterations in disease states.
3.4. Further Research and Conclusions
Despite the clinical relevance of PNNs targeted for CNS repair and regeneration, particularly in
locomotor recovery models of SCI, the functional relationship between PNNs and the motor system
is still mostly unexplored. Further research is required to look at the normal functional properties of
PNNs surrounding Mns. Additionally, the molecular heterogeneity of PNNs displayed in spinal Mns
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may indicate a functional role. However, understanding how the varying molecular heterogeneity of
PNNs affects CNS functions is a topic still in its infancy.
Though this study begins to address a research gap surrounding the properties of PNNs in
the spinal cord, much characterisation remains to be done. While ChABC has been an invaluable
investigative tool for understanding the role of PNNs in promoting plasticity and functional recovery
after SCI, there are clinical limitations to its therapeutic use. It is hoped that insights into the properties
of PNNs and their role in the spinal cord could aid the generation of alternative and non-invasive
strategies for targeted PNN removal to enhance functional recovery post-injury.
4. Materials and Methods
4.1. Animals
Female Lister Hooded rats (200–250 g; n = 5) were obtained from Charles River Laboratories
(Canterbury, UK) and were housed in groups in Central Biomedical Services (University of Leeds) in
a temperature controlled environment (20 ± 1 ◦C), with a 12 h light/dark cycle (lights on at 07:00).
Access to food and water was ad libitum. All procedures and experiments complied with the UK
Animals (Scientific Procedures) Act 1986.
4.2. Tissue Preparation
Animals were given an overdose of sodium pentobarbital (Pentoject; Henry Schein; 200 mg/kg;
intraperitoneal injection) to deeply anaesthetise without halting cardiac function. A transcardial
perfusion [56] was then performed using sodium phosphate buffer (PB; 0.12 M sodium phosphate
monobasic; 0.1 M NaOH; pH 7.4) followed by 4% paraformaldehyde (PFA; in PB; pH 7.4) for tissue
fixation. The spinal cord was dissected out, post-fixed in PFA (4%; 4 ◦C) overnight and cryoprotected
in 30% sucrose solution (30% v/w sucrose in PB; 4 ◦C) until tissue saturation. The appropriate cervical
(C3-T1), mid-thoracic and lumbar (L1-6) spinal cord segments were removed and frozen in optimum
temperature medium (OCT; Leica FSC 22 Frozen Section Media; Leica Biosystems) before storage at
−80 ◦C until sectioning. Tissue was cut using a cryostat (Leica CM1850; Leica Biosystems) into 40 µm
transverse sections. Sections were serially collected into 48-well plates containing physiological buffer
solution (PBS; 0.13 M NaCl, 0.7 M sodium phosphate dibasic, 0.003 M sodium phosphate monobasic;
pH 7.4) to remove the OCT before being transferred to 30% sucrose solution for storage at 4 ◦C.
4.3. Staining Procedures
Immunohistochemical techniques were used to label for cells in the spinal cord containing ChAT
and the PNNs surrounding subsets of these cells labelled by biotinylatedWisteria floribunda agglutinin
(bio-WFA) and CSPG components, including ACAN, BCAN and NCAN (Table 1). ChAT was used for
Mn identification [57] whilst WFA is universally used as a marker for PNNs [10,12].
At room temperature (RT), free-floating sections were washed three times for 5 min each in
Tris-buffered saline (TBS; 0.1 M tris base, 0.15 M NaCl; pH 7.4) to remove sucrose residue. Tissue
was then blocked in 0.3% TBST (1× TBS solution and 0.3% v/v Triton X-100) and 3% normal donkey
serum (NDS; v/v) for two hours. The sections were then transferred to co-incubate at 4 ◦C in blocking
buffer (3% NDS in 0.3% TBST; pH 7.4) containing the following primary antibodies: anti-ChAT (goat;
Millipore; 1:500; 48 h), biotin-conjugatedWisteria floribunda agglutinin (bio-WFA; Sigma; 1:150; 24 h)
and either ACAN (rabbit; Millipore; 1:250; 24 h), BCAN (mouse; DSHB; 1:500; 24 h), NCAN (mouse;
DSHB; 1:100; 24 h), VCAN (mouse; DSHB; 1:100; 24 h) or PTPRZ (mouse; DSHB; 1:80; 24 h) (Table 1).
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Table 1. Immunohistochemical detection of extracellular matrix components and neuronal markers, including concentration (conc.) of antibody used.
Detected Component Marker Host Antibody Conc. Source Characterisation
CSPGs
Aggrecan (mouse ACAN core protein) Anti-ACAN Rabbit polyclonal IgG 500 µg/mL Millipore #AB1031 WB2 (Lendvai et al., 2013 & Sutkus et al., 2014)
Brevican (BCAN; mouse cell-line derived
recombinant human Brevican)
Anti-BCAN Sheep polyclonal IgG 1 mg/mL R&D Systems #AF4009 WB2 (R&D Systems data sheet)
Neurocan (NCAN; N-terminal epitope) Anti-NCAN Mouse monoclonal IgG 369 µg/mL DSHB1 #1F6 WB2 (Asher et al., 2000 & Deepa et al., 2006)
Versican (VCAN; hyaluronate-binding region) Anti-VCAN Mouse monoclonal IgG 169 µg/mL DSHB1 #12C5 WB2 (Asher et al., 2002 & Deepa et al., 2006)
Phosphacan (PTPRZ) Anti- PTPRZ Mouse monoclonal IgG 165 µg/mL DSHB1 #3F8
WB2 (Deepa et al., 2006 &
Vitellaro-Zuccarello et al., 2006)
Lectins
N-acetylgalactosamine (GalNAc)
BiotinylatedWisteria
floribunda agglutinin (WFA)
N/A 2 mg/mL Sigma #L1766 Koppe et al., 1996
Neuronal markers
Choline acetyltransferase (ChAT) Anti-ChAT Goat polyclonal IgG - Millipore #AB144P -
Neuron-specific nuclear protein (NeuN) Anti-NeuN Mouse monoclonal IgG 1 mg/mL Millipore #MAB377 WB2 (Jin et al., 2003)
1 DSHB, Developmental Studies Hybridoma Bank, University of Iowa, USA. 2 WB, Western blotting.
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Immunostaining was routinely carried out using tissue from different animals and differing spinal
segments. The combinations carried out in this study used the formula: ChAT—Bio-WFA—CSPG
marker using various antibodies from Table 1, including for the lecticans ACAN, BCAN, NCAN and
VCAN. To differentiate between alpha and gamma Mns [31,44], ChAT was co-stained with anti-NeuN
(mouse; Millipore; 1:500; 24 h). Antibodies requiring 24-h incubation were added and mixed well 48 h
into a 72-h incubation with ChAT, using the protocols as above. To visualise each primary antibody
staining, the tissue was then co-incubated with the appropriate species of fluorescent-conjugated
secondary antibodies (1:500; 2 h; RT; Table 2).
Table 2. Fluorescent-conjugated secondary antibodies (2 mg/mL) used for immuno-detection of
primary antibodies.
Antibody Host Source
Alexa fluor 488 chicken anti-goat IgG Invitrogen #A21467
Alexa fluor 568 donkey anti-mouse IgG Invitrogen #A31571
Alexa fluor 568 donkey anti-rabbit IgG Invitrogen #A10042
Alexa fluor 568 donkey anti-sheep IgG Invitrogen #A21099
Alexa fluor 647 Streptavidin-conjugated Invitrogen #S32357
4.4. Image Acquisition and Quantification Methods
The fluorophores used to label the spinal cord sections were visualised using a Zeiss LSM
880 (upright) confocal microscope and were used to generate tile scans of the entire spinal cord
transverse section at 20× magnification (1.03 µs per pixel, averaging: 4). ChAT-positive cells and
co-localisation with WFA-positive PNNs and other CSPG-positive PNNs were counted using the Cell
Counter plugin (Kurt de Vos; https://imagej.nih.gov/ij/plugins/cell-counter.html) in the software
FIJI [58]. Mns were identified by location within the ventral horn of ChAT-positive cellular staining.
All ChAT-positive cells were individually counted and sequentially analysed for presence of PNN
staining. PNNs were only counted around ChAT-positive neurones and were identified by the presence
of intense staining as a bright ‘halo’ directly adjacent to the perimeter of ChAT-positive cells. Positive
PNN staining was categorised into three classes: (1) only WFA-positive, (2) only positive for the
appropriate CSPG stain or (3) WFA-positive and CSPG-positive. For differentiation of alpha and
gamma Mns, cells co-localising both ChAT and NeuN staining where taken as alpha Mns whereas the
absence of NeuN denoted gamma Mns [44,59].
4.5. Experimental Design and Statistical Analysis
A minimum of three sections per spinal level (cervical, thoracic or lumbar) per animal (n = 5)
were stained and imaged, maintaining the same confocal microscopy settings per staining procedure.
All counts per section were normalised by the number of ChAT-positive cells before averaging per
animal. All data sets were analysed with OriginPro 2016 scientific graphing and data analysis software
(OriginLab, Northampton, MA, USA), where results were statistically significant given that p < 0.05.
To test the influence of spinal cord level on PNN expression and for differences between PNN
types, results were pooled and analysed using one-way ANOVA, with Bonferroni correction for
between-groups multiple comparison.
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ACAN Aggrecan core protein
BCAN Brevican core protein
ChAT Choline acetyltransferase
ChABC Chondroitinase ABC
CNS Central nervous system
CS-GAG Chondroitin sulphate glycosaminoglycan
CSPGs Chondroitin sulphate proteoglycans
ECM Extracellular matrix
GalNAc N-acetylgalactosamine
HA Hyaluronic acid/hyaluronan
Mn Motoneurone
NeuN Neuron-specific nuclear protein
NCAN Neurocan core protein
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